1-12 of 12
Aileen Cohen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Megan (Der Yu) Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2022-171538
Published: 2022
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin Freeman, Moshe Yair Levy, Houston Holmes, Charles M. Farber, Arvind Chaudhry, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Kunthel By, Jane Huang, Jeff P. Sharman
Journal: Blood
Blood (2022) 140 (Supplement 1): 3655–3657.
https://doi.org/10.1182/blood-2022-159726
Published: 2022
Journal Articles

Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies

Linlin Xu, Mazyar Shadman, Anusha Ponakala, Ian W. Flinn, Moshe Yair Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Aileen Cohen, Dih-Yih Chen, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9269–9271.
https://doi.org/10.1182/blood-2022-167758
Published: 2022
Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial

Alessandra Tedeschi, Emmanuelle Ferrant, Ian W. Flinn, Constantine S. Tam, Paolo Ghia, Tadeusz Robak, Jennifer R. Brown, Vanitha Ramakrishnan, Tian Tian, Sowmya B. Kuwahara, Jason C. Paik, Aileen Cohen, Jane Huang, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 67.
https://doi.org/10.1182/blood-2021-144336
Published: 2021
Journal Articles

Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies

Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Jennifer L. Cultrera, Jamal Misleh, Syed F. Zafar, Benjamin Freeman, Subramanya S. Rao, Habte Yimer, Arvind Chaudhry, Mitul D. Gandhi, Troy H. Guthrie, Edwin Kingsley, Praveen K. Tumula, Sudhir Manda, Dih-Yih Chen, Aileen Cohen, Kunthel By, Linlin Xu, Ye Liu, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1410.
https://doi.org/10.1182/blood-2021-148544
Published: 2021
Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Constantine S. Tam, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Tian Tian, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 396.
https://doi.org/10.1182/blood-2021-148457
Published: 2021
Journal Articles

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Mazyar Shadman, MD MPH, Jeff P Sharman, MD, Moshe Y. Levy, MD, Jamal Misleh, MD, Syed F. Zafar, MD, Benjamin B. Freeman, MD, John M. Burke, MD, Jennifer L. Cultrera, MD, Habte A. Yimer, MD, Dih-Yih Chen, MD, Xiaoping Zhang, MD, Aileen Cohen, MD PhD, Sunhee Ro, PhD, Jane Huang, MD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–52.
https://doi.org/10.1182/blood-2020-134621
Published: 2020
Journal Articles

Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial

Constantine S. Tam, MBBS, MD, Ian W. Flinn, MD PhD, Alessandra Tedeschi, MD, Emmanuelle Ferrant, MD, Jennifer R. Brown, MD PhD, Tadeusz Robak, MDPhD, Paolo Ghia, MD PhD, Sowmya B. Kuwahara, PharmD, Jason C. Paik, MD PhD, Lei Hua, PhD, Aileen Cohen, MD PhD, Jane Huang, MD, Peter Hillmen, MBChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-134179
Published: 2020
Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón Garcia Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward Libby, Jeffrey V. Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trneny, Monique C. Minnema, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y. Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios Dimopoulos
Journal: Blood
Blood (2020) 136 (18): 2038–2050.
https://doi.org/10.1182/blood.2020006844
Published: 2020
Includes: Supplemental data
Journal Articles

Azacitidine (AZA) and Decitabine (DAC) Show Differential Effects On DNA Methyltransferase (DNMT) Levels in Patients with High Risk (HR) Myelodysplastic Syndrome (MDS)

Aileen Cohen, M.D., Ph.D., Ying-Wen Huang, MS, Rachael E. Hawtin, Ph.D., Jodi R. Ware, PharmD, Alessandra Cesano, M.D., Ph.D., Steven M. Kornblau, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 4906.
https://doi.org/10.1182/blood.V120.21.4906.4906
Published: 2012
Journal Articles

Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421

Norman J. Lacayo, MD, Aileen Cohen, Ph.D., M.D., Matt Westfall, Ph.D., Alan Lackey, MS, Xiaohua (Robert) Xin, Ph.D., M.D., Urte Gayko, Ph.D., Santosh Putta, Ph.D., Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Todd A. Alonzo, PhD, Robert J. Arceci, MD, PhD, Yaddanapudi Ravindranath, MD, Gary Van Houten Dahl, MD, Alessandra Cesano, MD
Journal: Blood
Blood (2010) 116 (21): 954.
https://doi.org/10.1182/blood.V116.21.954.954
Published: 2010
Journal Articles

Distinct Proteomic Signaling Networks Stratify Responses to Ara-C Based Induction Therapy in Patients with Acute Myeloid Leukemia (AML)

Mark Minden, David Rosen, Santosh Putta, Aileen Cohen, Helen Francis-Lang, Todd Covey, John Woronicz, David Soper, Brian Long, James Cordeiro, Lootsie Panganiban-Lustan, Steve Banville, Urte Gayko, Alessandra Cesano, Wendy Fantl
Journal: Blood
Blood (2008) 112 (11): 2549.
https://doi.org/10.1182/blood.V112.11.2549.2549
Published: 2008